On FDA's more day-to-day responsibilities, Gottlieb continued a multi-decade, bipartisan shift toward faster, more streamlined product reviews for drugs and medical devices. That issue has long been the top priority for the powerful pharmaceutical and device industries, which spend millions lobbying Congress and the federal government annually to ensure speedy market access for their products.
Ngaphakathi kwezibophezelo eziningi zosuku nosuku, u-Gottlieb waqhuba ukugudluka kweminyaka engamashumi amaningi yokusebenzisana ngababili, ukubuyekeza umkhiqizo ngokugudluka okushesha kakhulu nokuqondisiwekwezidakamizwa kanye nezisetshenziswa zokwelapha. Lolo daba kudala lingolubekwe phambili olusemqoka kuzimboni zokwenza imithi nezisetshenziswa ezinamandla,  ezisebenzisa amamiliyoni zicela uKhongolose kanye nohulumeniwenhlangano yamazwe ngonyaka nonyaka ukuqinisekisa ukufinyelela ngokushesha kwemikhiqizo yabo ezimakethe